Daclizumab Has Winning Efficacy In MS, But Safety Questions Linger
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Top-line results from a Phase IIb trial of Biogen Idec Inc./Abbott Laboratories Inc.'s daclizumab in relapsing-remitting multiple sclerosis are impressive, but data from an ongoing Phase III trial may clear up lingering questions about the drug's safety profile.